期刊文献+

高血压相关的骨折与钙通道阻滞剂 被引量:5

原文传递
导出
摘要 近年来,我国〉60岁人群中高血压的发病率为49%,数量超过8000万,居世界各国首位。文献报道,我国〉50岁人群骨折总患病率为26.6%。由此可见,高血压和骨折均是老年人中的常见病,且严重危害着公共健康。钙通道阻滞剂(CCB)类药物是老年高血压治疗的最常用药物之一,一项关于CCB类药物与骨折风险关系的较大规模的病例对照研究表明:CCB类药物与骨折风险降低相关。那么,CCB类药物能否在降压的同时作用于高血压相关的骨折呢?我们通过近年相关研究的复习,探讨高血压相关的骨折和CCB的关系。一。
作者 田小超 何青
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第3期236-237,共2页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献18

  • 1无,刘梅林(整理),郭艺芳(整理),胡大一.老年高血压的诊断与治疗中国专家共识(2011版)[J].中华内科杂志,2012,51(1):76-82. 被引量:163
  • 2薛延.骨质疏松症的流行病学概况[J].新医学,2007,38(1):7-8. 被引量:71
  • 3ARejnmark L, Vestergaard P, Mosekilde L. Treatment with beta- blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens ,2006,24:581-589.
  • 4Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet, 1999,354 : 971-975.
  • 5Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue Int, 2009,84 : 103-111.
  • 6Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep, 2008,6:77- 83.
  • 7Guan XX, Zhou Y, Li JY. Reciprocal Roles of Angiotensin II and Angiotensin II Receptors Blockade (ARB) in Regulating Cbfal/ RANKL via cAMP Signaling Pathway: Possible Mechanism for Hypertension-Related Osteoporosis and Antagonistic Effect of ARB on Hypertension-Related Osteoporosis. Int J Mol Sci, 2011,12 : 4206 4213.
  • 8Taguchi M, Takeuehi Y. Anabolie effects of statin and beta- blocker on bone metabolism. Clin Calcium, 2004,14:89-94.
  • 9Solomon DH, Mogun H, Garneau K,et al. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res, 2011,26 : 1561-1567.
  • 10Wiens M, Etminan M, Gill SS, et al. Effects of antihypertensive drug treatments on fracture outcomes : a meta-analysis of observational studies. J Intern Med ,2006,260:350-362.

二级参考文献16

  • 1李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量:1782
  • 21,Meszaros JG,Karin NJ,Akanbi K,et al.Down regulation of L-type Ca channeltranscript level by 1, 25-dihyroxyvitamin D3.Osteoblastic cells express L-type alphal1C Ca channel isoforms.J Biol Chem,1996,51:32981~32985.
  • 32,Guggino SE,Hajeunesse D,Wagner JA,et al.Bone remodeling signaled by a dihydropyridine-and phenylalkylamine-sensitive Calcium channel.Proc-Natl-Acad-Sci-USA,1989,86:2957~2960.
  • 43,Miyauchi A,Hruska KA,Greenfield EM,et al.Osteoclast cytosolic Calcium,regulated by voltage-gated Calcium channels and extracellular Calcium,controls podosome assembly and bone resorption.The Journal of Cell Biology,1990,111:2543~2552.
  • 54,Durieze J,Flautre B,Blary MC,et al.Effect of Calcium channel blocker Nifedipine on epiphyseal growth plate and bone turnover:a study in rabbit.Calcified Tissue International,1993,52:120~124.
  • 65,Messler HH,Koch W,Munzenberg KJ,et al.Analogous effect of orhanic Calcium antagonists and Msgnesium on the epiphyseal growth plate.Clinical Orthopaedics and related research Sep,1990,258:135~141.
  • 76,Zofkova I,Kancheva RL.The effect of Nifedipine on serum parathyroid homorne and calcitonin in postmenopausal women.Life Science,1995,11:1087~1096.
  • 87,Albers MM,Johnson W,Vivian V,et al.Chronic use of Calcium channel blocker Nifedipine has no significant effect on bone metabolism in men.Bone,1991,1:39~42.
  • 98,Frishman W H,Klein N A,Charlaop S,et al.Calcium channel antagonists in cardiovascular disease.Norwalk,CT,Appleton-Century-Crofts,1984,343~349.
  • 109,Seely EW,Leboff MS,Brown EM,et al.THE calcium channel blocker diltiazem lowers serum parathyroid levels in vitro and in vivo.J Clin Endocrinol Metab,1989,68:1007~1012.

共引文献238

同被引文献41

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部